ProMIS Neurosciences appoints Slanix Paul Alex, Pharm.D., to board of directors

ProMIS Neurosciences Inc.

Dr. Alex is President and Portfolio Manager for Ally Bridge Group, a major shareholder; joined board effective Oct 22, 2025.
He receives initial option for 40,000 common shares vesting 25% immediately, rest over 36 months; annual fee $40,000.
Company highlights upcoming data readouts from PRECISE-AD trial (PMN310) in 2Q26 and 4Q26.
Board determined Dr. Alex is independent under Nasdaq listing standards.
Ally Bridge Group has made multiple investments in ProMIS, including July 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.